{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Maharaj AR"],"funding":["NICHD NIH HHS","NCATS NIH HHS","National Institute of Child Health and Human Development"],"pagination":["542-554"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9008710"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["87(2)"],"pubmed_abstract":["<h4>Aims</h4>The aim of this study was to evaluate the population pharmacokinetics (PopPK) of olanzapine in children and devise a model-informed paediatric dosing scheme.<h4>Methods</h4>The PopPK of olanzapine was characterized using opportunistically collected plasma samples from children receiving olanzapine per standard of care for any indication. A nonlinear mixed effect modelling approach was employed for model development using the software NONMEM (v7.4). Simulations from the developed PopPK model were used to devise a paediatric dosing scheme that targeted comparable plasma exposures to adolescents and adults.<h4>Results</h4>Forty-five participants contributed 83 plasma samples towards the analysis. The median (range) postnatal age and body weight of participants were 3.8 years (0.2"],"journal":["British journal of clinical pharmacology"],"pubmed_title":["Population pharmacokinetics of olanzapine in children."],"pmcid":["PMC9008710"],"funding_grant_id":["HHSN267200700051C","HHSN275201000003C","K23 HD090239","R01 HD097775","HHSN275201000003I","UL1 TR002369","KL2 TR001115","UL1 TR002538","K23 HD091398"],"pubmed_authors":["Goldstein SL","Maharaj AR","Cohen-Wolkowiez M","Wu H","Al-Uzri A","Sherwin CMT","Payne EH","Zimmerman KO","Kalra R","Watt K","Erinjeri J","Hornik CP","Autmizguine J"],"additional_accession":[]},"is_claimable":false,"name":"Population pharmacokinetics of olanzapine in children.","description":"<h4>Aims</h4>The aim of this study was to evaluate the population pharmacokinetics (PopPK) of olanzapine in children and devise a model-informed paediatric dosing scheme.<h4>Methods</h4>The PopPK of olanzapine was characterized using opportunistically collected plasma samples from children receiving olanzapine per standard of care for any indication. A nonlinear mixed effect modelling approach was employed for model development using the software NONMEM (v7.4). Simulations from the developed PopPK model were used to devise a paediatric dosing scheme that targeted comparable plasma exposures to adolescents and adults.<h4>Results</h4>Forty-five participants contributed 83 plasma samples towards the analysis. The median (range) postnatal age and body weight of participants were 3.8 years (0.2","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Feb","modification":"2026-05-09T21:56:45.858Z","creation":"2025-04-04T13:30:52.622Z"},"accession":"S-EPMC9008710","cross_references":{"pubmed":["32497307"],"doi":["10.1111/bcp.14414"]}}